Table 1.
Patient and regional characteristics overall and according to whether patient received “Best Care” or not.
“Best care” (column %) | ||||
---|---|---|---|---|
N | No | Yes | p | |
Overall number of patients | 38,055 | 34,643 | 3,412 | |
Age | <0.001* | |||
66–69 | 12,940 | 34.4 | 29.9 | |
70–74 | 13,929 | 36.5 | 37.3 | |
75–79 | 8,180 | 21.2 | 24.2 | |
80–84 | 2,582 | 6.7 | 7.6 | |
85+ | 424 | 1.1 | 1.0 | |
Race | 0.060** | |||
White | 31,597 | 83.0 | 83.1 | |
Black | 3,646 | 9.5 | 10.1 | |
Hispanic | 640 | 1.7 | 1.1 | |
Asian | 1,031 | 2.7 | 2.7 | |
Other/Unknown | 1,141 | 3.0 | 3.0 | |
Comorbidity | 0.269* | |||
0 | 25,297 | 66.6 | 65.2 | |
1 | 8,586 | 22.5 | 23.4 | |
2 | 2,621 | 6.8 | 7.6 | |
3+ | 1,551 | 4.1 | 3.8 | |
Clinical stage | <0.001* | |||
T1 | 22,447 | 58.8 | 61.2 | |
T2 | 14,594 | 38.5 | 36.9 | |
T3/T4*** | 1,014 | 2.7 | 1.9 | |
Gleason Grade | 0.663* | |||
≤6 | 15,613 | 41.2 | 38.8 | |
7 | 16,335 | 42.5 | 46.8 | |
≥8 | 6,107 | 16.2 | 14.4 | |
Prostate Specific Antigen | 0.008* | |||
low (≤10 ng/ml) | 29,066 | 76.3 | 77.4 | |
intermediate | 6,036 | 15.8 | 16.5 | |
high (>20 ng/ml) | 2,953 | 7.9 | 6.1 | |
D’Amico risk | <0.001** | |||
Low | 11,758 | 31.3 | 27.3 | |
Intermediate | 15,144 | 38.9 | 48.6 | |
High | 11,153 | 29.8 | 24.1 | |
Year of diagnosis | 0.019* | |||
2004 | 6,738 | 17.9 | 15.6 | |
2005 | 6,332 | 16.7 | 16.3 | |
2006 | 6,831 | 17.8 | 19.6 | |
2007 | 7,130 | 18.7 | 18.9 | |
2008 | 6,264 | 16.4 | 16.7 | |
2009 | 4,760 | 12.5 | 12.9 | |
25% or more of adults in census tract with a college education | 18,477 | 48.2 | 53.2 | <0.001* |
Median annual household income of census tract | <0.001* | |||
Low (≤$40,784) | 12,484 | 33.7 | 24.7 | |
Intermediate | 12,654 | 33.2 | 34.7 | |
High (≥$59,938) | 12,855 | 33.2 | 40.6 | |
Residing in urban area | 34,465 | 90.1 | 95.6 | <0.001* |
Number of urologists per 100,000 men 65 and over | <0.001* | |||
Low (≤52) | 12,127 | 32.5 | 25.7 | |
Intermediate | 11,677 | 30.4 | 33.3 | |
High (≥87) | 14,247 | 37.1 | 41.0 | |
Number of radiation oncologists per 100,000 men 65 and over | 0.429* | |||
Low (≤21) | 12,394 | 32.5 | 33.7 | |
Intermediate | 12,200 | 32.2 | 30.8 | |
High (≥37) | 13,457 | 35.4 | 35.5 | |
Number of hospital beds per 100,000 men 65 and over | 0.528* | |||
Low (≤4,735) | 12,004 | 32.1 | 26.2 | |
Intermediate | 12,790 | 32.6 | 43.4 | |
High (≥6,854) | 13,257 | 35.3 | 30.4 | |
Medicare managed care penetration | <0.001* | |||
Low (≤4.8%) | 12,565 | 33.6 | 27.6 | |
Intermediate | 12,685 | 31.8 | 49.3 | |
High (≥16.0%) | 12,801 | 34.7 | 23.1 | |
Treatment received | <0.001** | |||
Open prostatectomy | 5,531 | 15.8 | 1.4 | |
Robotic prostatectomy | 4,496 | 12.2 | 7.5 | |
Brachytherapy | 12,903 | 29.9 | 74.4 | |
IMRT | 13,004 | 36.0 | 15.5 | |
EBRT | 2,121 | 6.0 | 1.1 |
Mantel-Haenszel chi-squared test;
Chi-squared test;
T3 and T4 were combined, because the SEER-Medicare data use agreement stipulates that cells with <11 cases must not be derivable (<100 patients had T4 disease).